Nuwellis, Inc. (NUWE)
NASDAQ: NUWE · IEX Real-Time Price · USD
0.148
+0.004 (2.43%)
Apr 30, 2024, 10:39 AM EDT - Market open
Nuwellis Revenue
In the year 2023, Nuwellis had annual revenue of $8.86M with 3.76% growth. Revenue in the quarter ending December 31, 2023 was $2.55M with 9.06% year-over-year growth.
Revenue (ttm)
$8.86M
Revenue Growth
+3.76%
P/S Ratio
0.11
Revenue / Employee
$150,237
Employees
59
Market Cap
1.01M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8.86M | 321.00K | 3.76% |
Dec 31, 2022 | 8.54M | 622.00K | 7.85% |
Dec 31, 2021 | 7.92M | 480.00K | 6.45% |
Dec 31, 2020 | 7.44M | 1.93M | 35.02% |
Dec 31, 2019 | 5.51M | 513.00K | 10.26% |
Dec 31, 2018 | 5.00M | 1.45M | 40.67% |
Dec 31, 2017 | 3.55M | 2.26M | 175.64% |
Dec 31, 2016 | 1.29M | 1.23M | 2,084.75% |
Dec 31, 2015 | 59.00K | -236.00K | -80.00% |
Dec 31, 2014 | 295.00K | 236.00K | 400.00% |
Dec 31, 2013 | 59.00K | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 407.00K | 183.00K | 81.70% |
Dec 31, 2009 | 224.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNUWE News
- 4 days ago - Nuwellis Announces Pricing of $2.7 Million Public Offering - GlobeNewsWire
- 7 weeks ago - Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference - GlobeNewsWire
- 2 months ago - Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 2 months ago - Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 - GlobeNewsWire
- 2 months ago - Nuwellis' Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™ - GlobeNewsWire
- 2 months ago - Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference - GlobeNewsWire
- 3 months ago - New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload - GlobeNewsWire